论文部分内容阅读
为观察大剂量国产尿激酶（UKTP）静脉溶栓治疗急性心肌梗塞（AMI）的临床有效性及安全性。152名急性心肌梗塞患者接收大剂量UKTP治疗。其中118例给予200万U，34例给予300万U，对其中41例溶栓后90分钟进行冠状动脉造影。结果显示：梗塞相关血管再通率为76．3％；90分钟冠状动脉造影开通率为80．5％；住院死亡率为5．3％；轻度出血发生率为14．5％；无大出血及脑卒中发生。比较200万U和300万U的临床疗效，结果显示300万U血管开通率及轻度出血发生率均有增加的趋势。结论：大剂量UKTP治疗AMI安全、可能提高血管开通率。
To observe the high-dose domestic urokinase (UKTP) intravenous thrombolytic therapy of acute myocardial infarction (AMI) clinical efficacy and safety. 152 patients with acute myocardial infarction receive high-dose UKTP treatment. 118 were given 2 million U and 34 were given 3 million U, and 41 of them underwent coronary angiography at 90 minutes after thrombolysis. The results showed that infarct-related vascular recanalization rate was 76.3%; 90-minute coronary angiography was 80.5%; in-hospital mortality was 5.3%; mild bleeding was 14.5%; no major bleeding And stroke. The clinical efficacy of 2 million U and 3 million U was compared. The results showed that the incidence of 3 million U vessels and mild bleeding increased. Conclusions: High-dose UKTP is safe for AMI and may increase the rate of vascular opening.